| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043619477 |
| P356 | DOI | 10.1038/BJC.1998.52 |
| P932 | PMC publication ID | 2151240 |
| P698 | PubMed publication ID | 9461007 |
| P5875 | ResearchGate publication ID | 13769864 |
| P2093 | author name string | Coleman RE | |
| Smith P | |||
| Rubens RD | |||
| P2860 | cites work | Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples | Q24569561 |
| Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years | Q24680218 | ||
| The clinical course of bone metastases from breast cancer | Q36027636 | ||
| High-dose intravenous pamidronate for metastatic bone pain | Q36079642 | ||
| Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. | Q39462829 | ||
| Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors | Q39760283 | ||
| Use of bisphosphonates in cancer patients | Q41346428 | ||
| Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. | Q41346437 | ||
| Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization | Q44058433 | ||
| Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group | Q44160812 | ||
| Parathyroid hormone related protein and skeletal morbidity in breast cancer | Q68132980 | ||
| Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer | Q70524877 | ||
| Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group | Q71890854 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 336-340 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Clinical course and prognostic factors following bone recurrence from breast cancer | |
| P478 | volume | 77 |
| Q37849622 | A novel hyperthermia treatment for bone metastases using magnetic materials |
| Q37393126 | A prospective study of bone tumor response assessment in metastatic breast cancer |
| Q36491537 | A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer |
| Q29619331 | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand |
| Q54451157 | Analysis of clinicopathological factors associated with bone metastasis in breast cancer. |
| Q39028702 | Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. |
| Q38018675 | Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes. |
| Q80477457 | Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists |
| Q34639893 | Bisphosphonates in the treatment of metastatic breast cancer |
| Q33727278 | Bone Metastases: An Overview |
| Q64109804 | Bone Metastasis Prognostic Factors in Breast Cancer |
| Q38153390 | Bone and cancer: the osteoncology |
| Q82494770 | Bone integrity and bone metastases in breast cancer |
| Q36648280 | Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. |
| Q37629662 | Bone metastasis risk factors in breast cancer. |
| Q34008243 | Bone metastasis: pathogenesis and therapeutic implications |
| Q39018130 | Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells |
| Q91782750 | Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment |
| Q33871528 | Breast cancer evaluation by fluorescent dot detection using combined mathematical morphology and multifractal techniques |
| Q35202963 | Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs |
| Q49318816 | Characterization of bone only metastasis patients with respect to tumor subtypes |
| Q64078856 | Clinical analysis of patients with skeletal metastasis of lung cancer |
| Q35164645 | Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates |
| Q33249084 | Clinical management of women with metastatic breast cancer: a descriptive study according to age group. |
| Q36295018 | Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma |
| Q26798170 | Contemporary approaches for imaging skeletal metastasis |
| Q81042479 | Cyberknife radiosurgery for breast cancer spine metastases: a matched-pair analysis |
| Q41489196 | Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial |
| Q37965768 | Denosumab and the current status of bone-modifying drugs in breast cancer |
| Q57758305 | Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study |
| Q50548682 | Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis |
| Q36442668 | Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts |
| Q37903673 | Dose-Fractionation Schedules for Radiotherapy of Bone Metastases |
| Q45954755 | Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. |
| Q40115101 | Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. |
| Q35998694 | Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients |
| Q35113022 | Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer |
| Q84920040 | Importance of the development time of isolated bone metastasis in breast cancer |
| Q94571941 | Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study |
| Q41594636 | Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid |
| Q39579106 | Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis |
| Q28202285 | Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases |
| Q39491821 | Is the assessment of the central skeleton sufficient for osseous staging in breast cancer patients? A retrospective approach using bone scans |
| Q38629732 | Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer |
| Q24597798 | Mechanisms of bone metastases of breast cancer |
| Q91766790 | Metastatic Breast Cancer in Kenya: Presentation, Pathologic Characteristics, and Patterns-Findings From a Tertiary Cancer Center |
| Q33903716 | Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis |
| Q80466001 | Metastatic breast carcinoma confined to bone: portrait of a clinical entity |
| Q48315762 | Modeling and integral X-ray, optical, and MRI visualization of multiorgan metastases of orthotopic 4T1 breast carcinoma in BALB/c mice |
| Q38155649 | Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor |
| Q39426582 | Mono- and Combined Therapy of Metastasizing Breast Carcinoma 4T1 with Zoledronic Acid and Doxorubicin |
| Q46958401 | Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. |
| Q36323486 | Novel mouse mammary cell lines for in vivo bioluminescence imaging (BLI) of bone metastasis |
| Q43287369 | Patterns of relapse in breast cancer: changes over time |
| Q36144917 | Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease |
| Q73231229 | Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer |
| Q38071245 | Predictors of early distant metastasis in women with breast cancer |
| Q37094622 | Prognostic factors for patients with bone-only metastasis in breast cancer |
| Q37321930 | Prognostic factors in 1,038 women with metastatic breast cancer |
| Q45756790 | Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis |
| Q44827346 | Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases |
| Q40764403 | Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma |
| Q73372249 | Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma |
| Q47547365 | Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis |
| Q47651148 | Quality of life (QOL) and symptom burden (SB) in patients with breast cancer |
| Q36036136 | Radionuclide Therapy of Bone Metastases |
| Q44543470 | Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using ass |
| Q28195767 | Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] |
| Q28242046 | Relevance of breast cancer cell lines as models for breast tumours: an update |
| Q37483543 | Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases |
| Q73549429 | Risk of complications from bone metastases in breast cancer. implications for management |
| Q39479158 | Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment |
| Q26822732 | Role of bone-anabolic agents in the treatment of breast cancer bone metastases |
| Q33506542 | Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. |
| Q57493778 | Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis |
| Q38746971 | Spine Surgery in Patients with Metastatic Breast Cancer: A Retrospective Analysis |
| Q34079207 | Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases |
| Q83332643 | Sternal resection and reconstruction after malignant tumours |
| Q35573228 | Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval |
| Q89314569 | The Osteoclast in Bone Metastasis: Player and Target |
| Q33757655 | The biology and management of bone metastases |
| Q53525038 | The implication of hot spots on bone scans within the irradiated field of breast cancer patients treated with mastectomy followed by radiotherapy. |
| Q90465793 | The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice |
| Q34617864 | The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors |
| Q38835815 | The β-catenin signaling pathway induces aggressive potential in breast cancer by up-regulating the chemokine CCL5. |
| Q37710370 | Treatment of painful bone metastases |
| Q35584408 | Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis |
| Q97426733 | Tumor dormancy in bone |
| Q35012766 | Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. |
| Q60912546 | Upregulated osterix promotes invasion and bone metastasis and predicts for a poor prognosis in breast cancer |
Search more.